Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
4/29/2026, 12:00:00 AM
Announced on 2026-04-29 that its self-developed Class 1 new drug, HS-10522 tablets, received two clinical trial approvals from China's NMPA for treating uncontrolled hypertension and primary aldosteronism. Medium importance is assigned as clinical approvals for new drugs typically impact price by >=5%.
Korean Translation
2026-04-29에 자체 개발 1급 신약 HS-10522정이 중국 국가약품감독관리국(NMPA)으로부터 '조절되지 않는 고혈압' 및 '원발성 알도스테론증' 치료를 위한 2건의 임상시험을 승인받았음을 발표함. 신약 임상 승인은 통상 5% 이상의 주가 영향을 미치므로 'Medium'으로 분류함.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date on June 16, 2026, for the 2025 final cash dividend of RMB 14.3 per 10 shares, with payment on July 13, 2026, scheduled. This consistent dividend payout is estimated to have a minor positive impact on investor sentiment.
6/16/2026, 12:00:00 AM
Grand Pharmaceutical Group Ltd (512) · Other
Ex-dividend date for a proposed final dividend of HK$0.169 per share for the year ended December 31, 2025, on 2026-06-12 scheduled. Low importance as dividend ex-dates typically result in minor price adjustments.
6/12/2026, 12:00:00 AM
Hangzhou Tigermed Consulting Co Ltd (3347) · Other
Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.
6/2/2026, 12:00:00 AM
GRAIL Inc (GRAL) · Other
GRAIL to present additional data from the NHS-Galleri trial at the 2026 ASCO Annual Meeting on May 30, 2026, scheduled. High importance estimated as clinical data is a key valuation driver.
5/30/2026, 12:00:00 AM
ANTA Sports Products Limited (2020) · Other
Ex-dividend date for the final FY2025 dividend of HK$1.08 per share is scheduled for May 15, 2026.
5/15/2026, 12:00:00 AM